Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant

Jane S Myung, Grant D Aaker, Szil&aacute;rd KissDepartment of Ophthalmology, Weill Cornell Medical Center, New York, NY, USAPurpose: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex&reg;; Allergan, Inc, Irvine, CA) in noninfectious po...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jane S Myung, Grant D Aaker, Szil&aacute;rd Kiss
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/66ac5f88b0294b73b3f0fec029240d0b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66ac5f88b0294b73b3f0fec029240d0b
record_format	dspace
spelling	oai:doaj.org-article:66ac5f88b0294b73b3f0fec029240d0b2021-12-02T01:55:20ZTreatment of noninfectious posterior uveitis with dexamethasone intravitreal implant1177-54671177-5483https://doaj.org/article/66ac5f88b0294b73b3f0fec029240d0b2010-12-01T00:00:00Zhttp://www.dovepress.com/treatment-of-noninfectious-posterior-uveitis-with-dexamethasone-intrav-a5832https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Jane S Myung, Grant D Aaker, Szil&aacute;rd KissDepartment of Ophthalmology, Weill Cornell Medical Center, New York, NY, USAPurpose: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex&reg;; Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis.Methods: A retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7 mg intravitreal implant was performed. Complete ophthalmic examination including signs of inflammatory activity, visual acuity, fundus photography, fluorescein angiography, optical coherence tomography, and tolerability of the implant were assessed.Results: Six eyes of 4 consecutive patients treated with a total of 8 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Two patients presented with unilateral idiopathic posterior uveitis; 2 patients had bilateral posterior uveitis, one secondary to sarcoidosis and the other to Vogt-Koyanagi-Harada syndrome. All eyes showed clinical and angiographic evidence of decreased inflammation following implant placement. Mean follow-up time post-injection was 5.25 months. Four eyes received 1 and 2 eyes received 2 Ozurdex implants during the follow-up period. The duration of effect of the implant was 3 to 4 months. No serious ocular or systemic adverse events were noted during the follow-up period.Conclusions: In patients with noninfectious posterior uveitis, sustained-release dexamethasone 0.7 mg intravitreal implant may be an effective treatment option for controlling intraocular inflammation.Keywords: corticosteroids, dexamethasone implant, Ozurdex, uveitis Jane S MyungGrant D AakerSzil&aacute;rd KissDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 1423-1426 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Jane S Myung Grant D Aaker Szil&aacute;rd Kiss Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
description	Jane S Myung, Grant D Aaker, Szil&aacute;rd KissDepartment of Ophthalmology, Weill Cornell Medical Center, New York, NY, USAPurpose: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex&reg;; Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis.Methods: A retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7 mg intravitreal implant was performed. Complete ophthalmic examination including signs of inflammatory activity, visual acuity, fundus photography, fluorescein angiography, optical coherence tomography, and tolerability of the implant were assessed.Results: Six eyes of 4 consecutive patients treated with a total of 8 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Two patients presented with unilateral idiopathic posterior uveitis; 2 patients had bilateral posterior uveitis, one secondary to sarcoidosis and the other to Vogt-Koyanagi-Harada syndrome. All eyes showed clinical and angiographic evidence of decreased inflammation following implant placement. Mean follow-up time post-injection was 5.25 months. Four eyes received 1 and 2 eyes received 2 Ozurdex implants during the follow-up period. The duration of effect of the implant was 3 to 4 months. No serious ocular or systemic adverse events were noted during the follow-up period.Conclusions: In patients with noninfectious posterior uveitis, sustained-release dexamethasone 0.7 mg intravitreal implant may be an effective treatment option for controlling intraocular inflammation.Keywords: corticosteroids, dexamethasone implant, Ozurdex, uveitis
format	article
author	Jane S Myung Grant D Aaker Szil&aacute;rd Kiss
author_facet	Jane S Myung Grant D Aaker Szil&aacute;rd Kiss
author_sort	Jane S Myung
title	Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
title_short	Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
title_full	Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
title_fullStr	Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
title_full_unstemmed	Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
title_sort	treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/66ac5f88b0294b73b3f0fec029240d0b
work_keys_str_mv	AT janesmyung treatmentofnoninfectiousposterioruveitiswithdexamethasoneintravitrealimplant AT grantdaaker treatmentofnoninfectiousposterioruveitiswithdexamethasoneintravitrealimplant AT szilampaacuterdkiss treatmentofnoninfectiousposterioruveitiswithdexamethasoneintravitrealimplant
_version_	1718402781727948800

Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant

Ejemplares similares